Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Some Generics May Get To Skip Fed Study Requirement If US FDA Research Pans Out

Executive Summary

Office of Generic Drugs official says the FDA may be able to harmonize its requirements with regulators who do not have a blanket mandate.

You may also be interested in...



Generic Industry Market Forces May Impact GDUFA III Talks

AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.

At US Generic Association Annual Meeting, Worries About Sustainability

ANDA sponsors fret price erosion – and potential changes to 180-day exclusivity.

FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

US agency has received 'very few' inquiries about the drugs on the list since its release.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel